PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade

被引：91

作者：

Hirsch, Laure ^{[1
]}

Zitvogel, Laurence ^{[2
]}

Eggermont, Alexander ^{[3
]}

Marabelle, Aurelien ^{[1
,2
]}

机构：

[1] Univ Paris Saclay, Dept Innovat Therapeut & Essais Precoces, Gustave Roussy, F-94805 Villejuif, France

[2] Univ Paris Saclay, INSERM, U1015, Gustave Roussy, F-94805 Villejuif, France

[3] Univ Paris Saclay, Gustave Roussy, F-94805 Villejuif, France

来源：

BRITISH JOURNAL OF CANCER | 2019年 / 120卷 / 01期

关键词：

OPEN-LABEL; NIVOLUMAB; PEMBROLIZUMAB; MULTICENTER; SAFETY; DOCETAXEL;

D O I：

10.1038/s41416-018-0294-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers ('PD-Lomas') is driving the clinical research strategies for the next generation of combination immunotherapy.

引用

页码：3 / 5

页数：3

共 50 条

[1] PD-1/PD-L1 Axis in Lung Cancer
Santini, Fernando C.
Hellmann, Matthew D.
CANCER JOURNAL, 2018, 24 (01) : 15 - 19
[2] PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
Huang, Changsheng
Ren, Shengxiang
Chen, Yaqi
Liu, Anyi
Wu, Qi
Jiang, Tao
Lv, Panjing
Song, Da
Hu, Fuqing
Lan, Jingqing
Sun, Li
Zheng, Xue
Luo, Xuelai
Chu, Qian
Jia, Keyi
Li, Yan
Wang, Jun
Zou, Caicun
Hu, Junbo
Wang, Guihua
SCIENCE ADVANCES, 2023, 9 (21)
[3] PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
Inoue, Yusuke
Osman, Murat
Suda, Takafumi
Sugimura, Haruhiko
TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S199 - S202
[4] PD-1/PD-L1 blockade in renal cell cancer
Beckermann, Kathryn E.
Johnson, Douglas B.
Sosman, Jeffrey A.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 77 - 84
[5] PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
Jia, Long
Zhang, Qi
Zhang, Rongxin
CANCER BIOLOGY & MEDICINE, 2018, 15 (02) : 116 - 123
[6] PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, Pedro Isaacsson
Antonarakis, Emmanuel S.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (05) : 475 - 486
[7] Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Shen, Xian
Zhao, Bin
BMJ-BRITISH MEDICAL JOURNAL, 2018, 362
[8] Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway
Barclay, Jonathan
Creswell, Joanne
Leon, Juan
ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (04): : 393 - 399
[9] Toxicities Associated With PD-1/PD-L1 Blockade
Wang, Daniel Y.
Johnson, Douglas B.
Davis, Elizabeth J.
CANCER JOURNAL, 2018, 24 (01) : 36 - 40
[10] Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade
Lee, Bo Ryeong
Chae, Sehyun
Moon, Jihyun
Kim, Myeong Joon
Lee, Hankyu
Ko, Hyuk Wan
Cho, Byoung Chul
Shim, Hyo Sup
Hwang, Daehee
Kim, Hye Ryun
Ha, Sang-Jun
JCI INSIGHT, 2020, 5 (14)

← 1 2 3 4 5 →